A Look At CG Oncology (CGON) Valuation As It Upsizes Its Planned US$550 Million Stock Offering

Simply Wall St.04-06

CG Oncology (CGON) has moved into focus after amending its planned stock offering to US$550 million from US$250 million, a sizeable raise that ties directly to ongoing clinical development and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625263806?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-06 06:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625263806","market":"nz","top_or_hot":-1,"title":"A Look At CG Oncology (CGON) Valuation As It Upsizes Its Planned US$550 Million Stock Offering","media":"Simply Wall St.","content":"<div>\n<p>CG Oncology (CGON) has moved into focus after amending its planned stock offering to US$550 million from US$250 million, a sizeable raise that ties directly to ongoing clinical development and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/a-look-at-cg-oncology-cgon-valuation-as-it-upsizes-its-plann\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At CG Oncology (CGON) Valuation As It Upsizes Its Planned US$550 Million Stock Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At CG Oncology (CGON) Valuation As It Upsizes Its Planned US$550 Million Stock Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-06 06:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/a-look-at-cg-oncology-cgon-valuation-as-it-upsizes-its-plann><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CG Oncology (CGON) has moved into focus after amending its planned stock offering to US$550 million from US$250 million, a sizeable raise that ties directly to ongoing clinical development and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/a-look-at-cg-oncology-cgon-valuation-as-it-upsizes-its-plann\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/a-look-at-cg-oncology-cgon-valuation-as-it-upsizes-its-plann","article_id":"2625263806","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/a-look-at-cg-oncology-cgon-valuation-as-it-upsizes-its-plann","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625263806","pubTimestamp":1775427535,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CG Oncology (CGON) has moved into focus after amending its planned stock offering to US$550 million from US$250 million, a sizeable raise that ties directly to ongoing clinical development and anticipated topline trial disclosures.\nSee our latest analysis for CG Oncology.\nThe latest stock offering news comes on top of strong share price momentum, with a 30 day share price return of 9.05%, a 90 day share price return of 68.53%, and a 1 year total shareholder return of about 3x. This suggests...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","CG":"凯雷","CGON":"CG Oncology Inc.","BK4135":"资产管理与托管银行","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"CG Oncology(CGON)扩大其5.5亿美元股票发行计划的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGON":1.5,"CG":1.5,"DCF":1},"content_text":"CG Oncology (CGON) has moved into focus after amending its planned stock offering to US$550 million from US$250 million, a sizeable raise that ties directly to ongoing clinical development and anticipated topline trial disclosures. See our latest analysis for CG Oncology. The latest stock offering news comes on top of strong share price momentum, with a 30 day share price return of 9.05%, a 90 day share price return of 68.53%, and a 1 year total shareholder return of about 3x. This suggests investors are increasingly focused on CG Oncology’s clinical and funding progress. If this type of move has your attention, it could be a good time to see what else is setting the pace among healthcare focused AI names using our 36 healthcare AI stocks. With CG Oncology shares near record levels, a larger offering on the table, and analyst targets still above the current price, the key question is whether the stock is still mispriced or if markets already assume years of future growth. AdvertisementPreferred Price to Book of 7.6x: Is It Justified? CG Oncology last closed at $67.48, and on a P/B of 7.6x it screens as expensive against the broader US biotechs group, even though analysts still see upside from here. P/B compares the company’s market value to its book value, which is essentially net assets on the balance sheet. For an early stage biopharma with limited revenue and ongoing losses, a higher P/B often reflects how much investors are willing to pay today for potential future cash flows tied to the pipeline rather than current financials. In CG Oncology’s case, the 7.6x P/B sits well above the US biotechs industry average of 2.2x. This points to a rich valuation relative to the sector. However, it is below the peer group average of 10.3x, suggesting the stock carries a premium to the wider industry but trades at a discount to closer comparables that investors may see as similar in profile and stage. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 7.6x (OVERVALUED) However, the story can quickly change if clinical trial data underwhelms expectations or if the larger US$550 million raise affects sentiment by diluting existing shareholders. Find out about the key risks to this CG Oncology narrative. Another View: DCF Points the Other Way While the 7.6x P/B ratio makes CG Oncology look expensive compared with the broader US biotechs group, the SWS DCF model points in the opposite direction. At a share price of $67.48 versus an estimated future cash flow value of $301.75, the stock appears deeply undervalued on this framework. This gap suggests either the market is heavily discounting execution and trial risks, or the DCF assumptions are more optimistic than sentiment implies. For you, the tension is clear: which story feels closer to reality as new data and funding decisions come through. Look into how the SWS DCF model arrives at its fair value. CGON Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CG Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps The mixed signals on valuation and sentiment mean the next move is not obvious. Move quickly, review the data yourself, and weigh the 3 key rewards and 1 important warning sign. Looking for more investment ideas? If CG Oncology has sharpened your interest, do not stop here. Use focused stock lists to uncover other opportunities that match your risk, income, and quality preferences.  Target potential mispricings by scanning companies that combine quality metrics with attractive valuations using the 58 high quality undervalued stocks. Strengthen your income stream by reviewing businesses that offer 5%+ yields in the 13 dividend fortresses. Focus on financial resilience by checking companies that appear on the solid balance sheet and fundamentals stocks screener (40 results).   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625263806","isCrawlerRequest":true}